Sebastien Carnicella

List of Publications by Year
in descending order

48 papers	2,753 citations	236925 25 h-index	276875 41 g-index
54 all docs	54 docs citations	54 times ranked	2961 citing authors

#	Article	IF	Citations
1	A metabolic biomarker predicts Parkinsonâ€™s disease at the early stages in patients and animal models. Journal of Clinical Investigation, 2022, 132, .	8.2	12
2	Dopamine D3 Receptors: A Potential Target to Treat Motivational Deficits in Parkinsonâ€™s Disease. Current Topics in Behavioral Neurosciences, 2022, , 109-132.	1.7	4
3	GPCR and Alcohol-Related Behaviors in Genetically Modified Mice. Neurotherapeutics, 2020, 17, 17-42.	4.4	8
4	Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. PLoS ONE, 2020, 15, e0238156.	2.5	20
5	Reply to: Letter to the Editor by MartÃnezâ€FernÃ¡ndez. Movement Disorders, 2020, 35, 1084-1085.	3.9	0
6	Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease. Movement Disorders, 2020, 35, 616-628.	3.9	20
7	Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. , 2020, 15, e0238156.		0
8	Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. , 2020, 15, e0238156.		0
9	Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. , 2020, 15, e0238156.		0
10	Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats. , 2020, 15, e0238156.		0
11	Plasma or serum? A qualitative study on rodents and humans using high-throughput microRNA sequencing for circulating biomarkers. Biology Methods and Protocols, 2019, 4, bpz006.	2.2	38
12	DREADDs: The Power of the Lock, the Weakness of the Key. Favoring the Pursuit of Specific Conditions Rather than Specific Ligands. ENeuro, 2019, 6, ENEURO.0171-19.2019.	1.9	28
13	Nigrostriatal Dopaminergic Denervation Does Not Promote Impulsive Choice in the Rat: Implication for Impulse Control Disorders in Parkinsonâ€™s Disease. Frontiers in Behavioral Neuroscience, 2018, 12, 312.	2.0	12
14	Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 41589.	3.3	15
15	Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease. Movement Disorders, 2017, 32, 1566-1573.	3.9	61
16	Reversing dopaminergic sensitization. Movement Disorders, 2017, 32, 1679-1683.	3.9	12
17	Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinsonâ€™s Disease?. Frontiers in Psychiatry, 2016, 7, 91.	2.6	28
18	Emotional manifestations of PD: Neurobiological basis. Movement Disorders, 2016, 31, 1103-1113.	3.9	79

#	Article	IF	Citations
19	What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinsonâ€™s disease?. Translational Psychiatry, 2016, 6, e753-e753.	4.8	60
20	Motivational Deficits in Parkinsonâ€™s Disease: Role of the Dopaminergic System and Deep-Brain Stimulation of the Subthalamic Nucleus. Innovations in Cognitive Neuroscience, 2016, , 363-388.	0.3	0
21	Apathy and Impulse Control Disorders: YinÂ& Yang of Dopamine Dependent Behaviors. Journal of Parkinson's Disease, 2015, 5, 625-636.	2.8	67
22	Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats. Movement Disorders, 2015, 30, 1739-1749.	3.9	25
23	Implication of dopamine D3 receptor activation in the reversion of Parkinsonâ€™s disease-related motivational deficits. Translational Psychiatry, 2014, 4, e401-e401.	4.8	58
24	Pramipexole reverses Parkinson's diseaseâ€related motivational deficits in rats. Movement Disorders, 2014, 29, 912-920.	3.9	55
25	Intermittent ethanol access schedule in rats as a preclinical model of alcohol abuse. Alcohol, 2014, 48, 243-252.	1.7	257
26	Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinsonâ€™s disease. Molecular Psychiatry, 2014, 19, 358-367.	7.9	166
27	Ethanol-Mediated Facilitation of AMPA Receptor Function in the Dorsomedial Striatum: Implications for Alcohol Drinking Behavior. Journal of Neuroscience, 2012, 32, 15124-15132.	3.6	83
28	The Small G Protein H-Ras in the Mesolimbic System Is a Molecular Gateway to Alcohol-Seeking and Excessive Drinking Behaviors. Journal of Neuroscience, 2012, 32, 15849-15858.	3.6	36
29	Subthalamic stimulation in Parkinsonâ€™s disease: restoring the balance of motivated behaviours. Brain, 2012, 135, 1463-1477.	7.6	275
30	AKT Signaling Pathway in the Nucleus Accumbens Mediates Excessive Alcohol Drinking Behaviors. Biological Psychiatry, 2011, 70, 575-582.	1.3	104
31	Regulation of Operant Oral Ethanol Self-Administration: A Dose-Response Curve Study in Rats. Alcoholism: Clinical and Experimental Research, 2011, 35, 116-125.	2.4	27
32	Glial Cell Line-Derived Neurotrophic Factor Reverses Alcohol-Induced Allostasis of the Mesolimbic Dopaminergic System: Implications for Alcohol Reward and Seeking. Journal of Neuroscience, 2011, 31, 9885-9894.	3.6	74
33	Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats. International Journal of Neuropsychopharmacology, 2010, 13, 109.	2.1	3
34	Noribogaine, but not 18â€MC, exhibits similar actions as ibogaine on GDNF expression and ethanol selfâ€administration. Addiction Biology, 2010, 15, 424-433.	2.6	35
35	Long-Lasting Adaptations of the NR2B-Containing NMDA Receptors in the Dorsomedial Striatum Play a Crucial Role in Alcohol Consumption and Relapse. Journal of Neuroscience, 2010, 30, 10187-10198.	3.6	161
36	Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20093-20098.	7.1	140

#	Article	IF	Citations
37	Nucleus Accumbens-Derived Glial Cell Line-Derived Neurotrophic Factor Is a Retrograde Enhancer of Dopaminergic Tone in the Mesocorticolimbic System. Journal of Neuroscience, 2010, 30, 14502-14512.	3.6	39
38	Endogenous BDNF in the Dorsolateral Striatum Gates Alcohol Drinking. Journal of Neuroscience, 2009, 29, 13494-13502.	3.6	167
39	GDNF â€" A potential target to treat addiction. , 2009, 122, 9-18.		78
40	GDNF is an Endogenous Negative Regulator of Ethanolâ€Mediated Reward and of Ethanol Consumption After a Period of Abstinence. Alcoholism: Clinical and Experimental Research, 2009, 33, 1012-1024.	2.4	40
41	Excessive alcohol consumption is blocked by glial cell lineâ€"derived neurotrophic factor. Alcohol, 2009, 43, 35-43.	1.7	108
42	Cabergoline Decreases Alcohol Drinking and Seeking Behaviors Via Glial Cell Line-Derived Neurotrophic Factor. Biological Psychiatry, 2009, 66, 146-153.	1.3	40
43	GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8114-8119.	7.1	117
44	Ã‰laboration dâ€™un modÃ¨le de psychose dÃ©lirante chez le rat ayant une validitÃ© thÃ©orique. , 2008, , 179-195.		0
45	Ethanol Induces Long-Term Facilitation of NR2B-NMDA Receptor Activity in the Dorsal Striatum: Implications for Alcohol Drinking Behavior. Journal of Neuroscience, 2007, 27, 3593-3602.	3.6	169
46	Fos immunolabelling evidence for brain regions involved in the Pavlovian degraded contingency effect and in its disruption by atropine. Neuropharmacology, 2006, 51, 102-111.	4.1	4
47	Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect. Psychopharmacology, 2005, 178, 533-541.	3.1	8
48	Cholinergic effects on fear conditioning I: the degraded contingency effect is disrupted by atropine but reinstated by physostigmine. Psychopharmacology, 2005, 178, 524-532.	3.1	10